Ershad Moradi, Author at Pharmuni

GMP SOPs Guide 2026: Master the Ultimate Compliance Framework for Pharma Excellence

April 1, 2026

Discover how mastering the GMP SOP framework drives pharmaceutical excellence. This guide explains why SOPs are living documents requiring ongoing updates, training, and reviews to maintain compliance and safeguard product quality. Learn key components, best practices, and global regulatory insights that empower pharma companies to excel in quality assurance and regulatory readiness.

Out of Trend (OOT) Masterclass 2026: Essential Strategies for Bulletproof Pharma Compliance

March 31, 2026

Out of Trend (OOT) results signal deviations in data that differ from expected norms, often acting as early warnings in pharmaceutical manufacturing. Ignoring these trends can lead to costly Out of Specification (OOS) failures, which account for nearly 20% of batch rejections globally

Master ICH Q7 Guideline in 2026: Essential API GMP Rules You Must Know

March 30, 2026

ICH Q7 is the GMP guide for active pharmaceutical ingredients (APIs). It sets detailed standards for quality, documentation, validation, and supplier control. WHO reports that poor supplier management causes up to 30% of API quality issues. Following ICH Q7 ensures consistent product safety and regulatory compliance worldwide.

Annual Product Review (APR) in Pharma in 2026: GMP Requirements, Steps, and Checklist

March 26, 2026

The Annual Product Review (APR) is a vital component in pharmaceutical quality systems, reviewing yearly product data to ensure compliance and identify improvement opportunities. It reinforces audit readiness by providing transparent, trend-based insights that drive continuous quality assurance and risk mitigation, ultimately safeguarding patient safety and regulatory compliance.

Audit Trail Review: Complete Guide to GMP Requirements, SOP Steps, and Inspection Readiness in 2026

March 25, 2026

Audit Trail Review is a critical process in pharmaceutical manufacturing that involves examining electronic records to ensure all entries, changes, and deletions are accurately documented and traceable. This review maintains data integrity, prevents errors, and detects unauthorized activities.

Release for Distribution in Pharma Manufacturing: a 2026 Guide on GMP Controls, Roles, and Required Documents

March 24, 2026

Release for Distribution requires Quality Unit authorization confirming all specifications met per WHO GDP Chapter 8, alongside logistics verification of temperature control, documentation, and shipping readiness before patient delivery. This dual authorization ensures regulatory compliance and product integrity throughout the supply chain. Understanding these processes prevents delays and protects patient safety by maintaining GMP standards and traceability requirements.

NDA Regulatory Affairs in 2026: Key Processes, Documents, and RA Responsibilities

March 13, 2026

NDA regulatory affairs work turns science into a review-ready submission. An NDA is the formal FDA marketing application for a new drug. FDA first runs a filing check within 60 days to confirm completeness. Then the team reviews the dossier. The CTD’s five-module structure, delivered through eCTD, improves consistency, traceability, and lifecycle management during review.

Sampling Plan in Pharma: GMP, FDA/EMA Expectations, and QC Workflow

March 13, 2026

A pharmaceutical sampling plan ensures that tested samples truly represent the entire batch. Because results determine product release, regulators require representative collection, justified sample size, controlled handling, and full documentation. Strong sampling practices reduce risk, support compliance, and protect patient safety.

GMP Packaging in 2026: Requirements, Guidelines, Controls, and Primary vs Secondary Packaging

March 12, 2026

GMP packaging protects product identity, quality, and traceability while preventing mix-ups and labeling errors. Strong controls such as line clearance, reconciliation, and component management ensure only correct, compliant products reach patients and markets.

More features